Now I have enough context. Let me produce my final review.

---

## Summary

This paper proposes an end-to-end framework for multi-view diabetic retinopathy (DR) grading that generates lesion proposals internally within the grading pipeline, eliminating the need for external lesion annotations at inference. The method introduces two modules: (1) GALP, which derives grade-conditioned evidence maps (GEMs) via CAM from auxiliary classifiers and selects top-K high-evidence regions as lesion proposals, and (2) LGRF, which performs cross-view fusion of these proposals via a gated mixture-of-experts with top-K-weighted cross-view attention. Experimental results on MFIDDR (four-view) and DRTiD (two-view) datasets show competitive accuracy (83.9% w/o lesion on MFIDDR, 76.0% on DRTiD) that matches or approaches externally-informed methods.

## Strengths

1. **Competitive quantitative results on two multi-view DR benchmarks.** The "Ours (w/o lesion)" variant achieves 83.9% accuracy on MFIDDR (Table 1), surpassing all end-to-end baselines and matching or exceeding several externally-informed methods such as CVSA (82.6%) and LFMVDR w/ lesion (82.2%). On DRTiD (Table 3), it achieves 76.0% accuracy, outperforming the prior best CrossFIT (75.6%) which uses OD and macula annotations. These results represent genuine empirical competitiveness.

2. **Ablation study isolating each module's contribution.** Table 4 shows consistent degradation when removing GALP (−1.2% acc), the expert pool (−1.3% acc), or LGRF (−1.6% acc) compared to the full method (83.9%). The consistency of these drops across all four reported metrics (Acc, Spe, Kappa, F1) supports the claim that both modules contribute meaningfully to performance.

3. **Grade-level breakdown (Table 2) and hyperparameter analysis (Fig. 3)** provide granularity beyond top-line metrics. The grade-level results show the method performs well across all severity grades (especially Grade 3 with F1=74.1% w/o lesion), and the hyperparameter analysis demonstrates non-trivial sensitivity (e.g., α=0.5 clearly outperforms α=0.2 or 0.7), indicating the design choices are empirically grounded rather than arbitrary.

## Weaknesses

### Fatal
None.

### Major

1. **No backbone-controlled baseline — the claimed gains cannot be cleanly attributed to the proposed modules.** The method uses Swin-B as its backbone, which is a substantially stronger architecture than the backbones used by most baselines in Tables 1 and 3 (ResNet50, VGG19, unspecified CNN hybrids). The ablation study (Table 4) does not include a plain Swin-B baseline — i.e., Swin-B with simple multi-view concatenation and a linear classifier, without GALP, LGRF, or any proposal mechanism. The "w/o LGRF" variant (82.3%) still uses GALP proposals concatenated across views; the "w/o GALP" variant (82.7%) still uses LGRF fusion with all tokens. Neither isolates the backbone. Without this baseline, it is unclear whether the 83.9% accuracy comes from GALP/LGRF or from Swin-B's inherent capacity. Moreover, the comparison with externally-informed methods is potentially confounded: claiming to "surpass" methods that use weaker backbones may reflect architecture choice rather than the proposed modules. A fair comparison would require at least ablating the proposed modules on the same backbone used by competitive baselines, or including a plain Swin-B row in Table 4.

2. **No qualitative or quantitative validation that the CAM-based proposals actually correspond to lesions.** The paper's central novelty is that GALP generates "lesion proposals" that "act as surrogates for expert cues" (Section 3.2). However, there are zero visualizations showing what these proposals look like — no overlaid CAM/GEM maps on fundus images, no side-by-side comparisons with ground-truth lesion masks, no example proposals. CAM-based class activation maps identify regions predictive of the grade, but "predictive of the grade" is not synonymous with "contains lesions." The model could learn to attend to non-lesion correlates of DR severity (vessel tortuosity, disc pallor, dataset-specific artifacts). Ablation Table 4 shows that GALP's token selection improves accuracy, but does not show *why* — the improvement could come from spatial attention / token sparsification generally, not from lesion-specific guidance. Given that MFIDDR provides lesion segmentation masks (used in the "with lesion" variant, Section 4.1), the authors could and should validate whether the proposals spatially overlap with actual lesions.

### Minor

3. **No statistical significance reporting for modest gains.** The paper reports no error bars, confidence intervals, or multiple-run statistics. This matters because several claimed advantages are small: the 0.4% gain over CrossFIT on DRTiD (76.0% vs 75.6%), and the 1.2–1.6% ablation drops on MFIDDR could plausibly fall within a single standard deviation of run-to-run variance. Reporting mean±std over 3–5 independent runs would substantially strengthen the empirical claims.

4. **Claim of improved micro-lesion sensitivity is asserted but not evaluated.** The paper claims in its contributions (lines 43–45) that the method "recovers small, low-contrast lesions" and "elevat[es] micro-lesion sensitivity," but no experiment measures lesion-level detection or sensitivity. The experiments evaluate only grade-level accuracy. While this is a secondary claim, it should either be supported or removed.

### Trivial
None.

## Nice-to-Haves

- Adding a plain Swin-B baseline (Swin-B + view-wise concatenation + linear classifier) to the ablation table would clarify whether the 1–2% improvements come from the proposed modules or the backbone.
- Visualizing the lesion proposals (e.g., overlaying top-K regions on fundus images alongside ground-truth lesion masks from MFIDDR) would directly validate the paper's central claim.
- An ablation comparing CAM-based proposal selection against random token selection would disentangle whether the benefit comes from CAM guidance or from token sparsification.
- Reporting training hyperparameters (optimizer, learning rate schedule, batch size, epochs, weight decay, augmentation strategy) would improve reproducibility.
- Justification or ablation of the design choice to fuse only the adjacent (cyclic) view rather than all other views.
- Analysis of computational cost (FLOPs, parameter count, inference time) for the added modules.

## Removed Points

These points were identified by reviewers but are removed from the main weakness list for the following reasons:

- **Criticism about micro-lesion sensitivity claim being "untested"** → The claim is genuine but secondary (Minor weakness 4 captures it). It does not undermine the core contribution.
- **Criticism about narrow y-axis ranges in Fig. 3** → A formatting nitpick with no substantive impact.
- **Criticism about stage 4 not having auxiliary/load losses (Eq. 2 vs Eq. 11 sum over n=1:3)** → Stage 4 features go directly to GAP and the final classifier (Section 3.4), so it is by design that no auxiliary classifier is needed at stage 4.
- **Criticism about cross-view fusion only using the adjacent view** → A design choice that could be ablated but is not a weakness in the standard sense. The choice is clearly stated (Section 3.3, line 123).
- **Ambiguity about expert routing design (averaged tokens for routing scores)** → A design choice, not an error. There is no evidence this is suboptimal.
- **Criticism about missing related works** → Removed per filtering rules (no external source to verify).
- **Criticism about missing appendix content** → Removed per filtering rules (parser strips appendices from all papers).

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Add a plain Swin-B baseline** (Swin-B + simple view-wise feature concatenation + linear classifier) to Table 4. This single addition would anchor the ablation and resolve the most serious confound in the paper.
2. **Visualize the lesion proposals.** Show overlays of the top-K GEM regions on several fundus images alongside ground-truth lesion masks (available on MFIDDR). This would directly validate the central claim that the proposals correspond to lesions.
3. **Report mean±std over multiple runs** (3–5 seeds) for the main results and ablation table, to allow assessment of statistical significance.
4. **Add an ablation comparing CAM-based vs. random token selection** to confirm that the benefit of GALP comes from lesion-specific guidance rather than general token sparsification.
5. **Provide complete training hyperparameters** (optimizer, learning rate, batch size, epochs, weight decay, data augmentation) in the main text.

## Score and Decision

### Calibration Anchors

| Anchor Paper | Avg Score | Round | Comparison |
|---|---|---|---|
| Dynamic Modeling...M4oE (medical MoE) | 5.75 | Round 2 | Similar domain and MoE components; M4oE accepted with comparable weaknesses re: significance and ablations |
| Dancing with Discrepancies (lesion segmentation) | 4.50 | Round 2 | Weaker presentation and methodology; rejected. This paper is clearer and better-motivated |
| Deep Incomplete Multi-view Learning | 6.25 | Round 2 | Stronger multi-view paper with more datasets and rigorous evaluation; this paper has more structural evidence gaps |
| Trusted Multi-View Classification | 6.25 | Round 2 | Broader experimental validation; this paper has a more specific, real-world motivation |
| DSPFusion (image fusion) | 4.60 | Round 2 | Rejected paper in different domain; this paper is stronger in clarity and task specificity |

### Bracket

**Round 1 bracket:** 4.0 – 6.0. **Round 2 (narrowing):** The comparison with M4oE (5.75, Accept on medical MoE with similar weaknesses) anchors the upper end, while the reject-range medical papers (4.0–4.6) anchor the lower end. This paper has a clearer real-world motivation than the reject-range papers but has more substantial evidence gaps (no backbone baseline, no proposal validation) than the accept-range papers.

**Final score: 5.0** — borderline reject. The core idea is well-motivated and the results are competitive, but the two major evidence gaps (missing backbone-controlled baseline, missing validation that proposals correspond to lesions) prevent clean attribution of the claimed contributions. These weaknesses are fixable with additional experiments.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>